Lilly Presents Updated Results of Retevmo (selpercatinib) in P-I/II (LIBRETTO-001) Trial for Advanced RET Fusion-Positive NSCLC at ELCC 2022
Shots:
- The P-I/II (LIBRETTO-001) trial evaluates Retevmo (40 & 80mg) in 355 patients with RET fusion+ NSCLC over 16 countries & 89 sites
- The results showed ORR (61.1%) in 247 patients prior treated with 1L of CT while ORR (84.1%) in 69 treatment-naïve with 58% receiving anti-PD-1 or anti-PD-L1 therapy, 26 patients had measurable CNS metastases at baseline, ORR (84.6%) with 22 patients had CR & PR
- Additionally, median intracranial PFS of 19.4mos. in 26 patients with measurable CNS disease at a median follow-up of ~2yr. in treatment-naïve and Pt- CT pretreated populations. The company continues to advance the therapy including an ongoing P-III confirmatory study & the results are expected in 2023
Ref: PR Newswire | Image: Eli Lilly
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
